The glycopeptide antibiotics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Glycopeptide Antibiotics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size —
The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.
The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, r&d investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Scope Of Glycopeptide Antibiotics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Glycopeptide Antibiotics Market Overview
Market Drivers –
The rising number of cancer and infectious disease cases is expected to propel the growth of the glycopeptide antibiotics market going forward. Cancer refers to a disease that occurs when certain body cells multiply beyond their limits and spread to other body regions, whereas, infectious diseases are disorders produced by organisms such as bacteria, viruses, fungus, or parasites. The glycopeptide antibiotics are used to treat a variety of infectious disorders caused by methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus bacteria that are resistant to beta-lactams and other antibiotics. In cancer patients, glycopeptide antibiotics are used to boost radiotherapy’s antitumor effects by eliminating not only the targeted cancer cells but also distant cancer cells farther in the body. For instance, according to the American Cancer Society, a US-based non-profit health organization committed to cancer eradication, in 2022, the US had 1.9 million new cancer cases and 609,360 cancer deaths, for a total of 1,670 fatalities each day. Therefore, the rising cancer and infectious disease cases will drive the growth of the glycopeptide antibiotics market.
Market Trends —
Product innovation is a key trend gaining popularity in the glycopeptide antibiotics market. Major companies operating in the glycopeptide antibiotics market are focused on developing innovative products to strengthen their position in the market. For instance, In October 2022, Leiden University, a Netherlands-based research university, discovered new variants of the antibiotic vancomycin. A group of molecules was attached to the structure of an existing vancomycin molecule to create the new variant antibiotic vancomycin. The new variant of vancomycin is up to a thousand times more active against gram-positive bacteria than the original vancomycin and has lower nephrotoxicity when compared to commercially utilized polymyxin antibiotics. This was created to solve the problem since vancomycin can only be effective against gram-positive strains and it cannot pass through the outer membrane (OM) of gram-negative bacteria.
The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Get an inside scoop of the glycopeptide antibiotics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp
Regional Insights —
North America was the largest region in the glycopeptide antibiotics market in 2023. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies —
Major companies operating in the glycopeptide antibiotics market report are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, Targanta Therapeutics, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc. .
Table of Contents
1. Executive Summary
2. Glycopeptide Antibiotics Market Report Structure
3. Glycopeptide Antibiotics Market Trends And Strategies
4. Glycopeptide Antibiotics Market — Macro Economic Scenario
5. Glycopeptide Antibiotics Market Size And Growth
…..
27. Glycopeptide Antibiotics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
